CIPLA LTD.

Cipla Ltd has issued an email communication to its members regarding the tax deduction at source (TDS) on the final dividend for FY 2025-26, which is to be declared at the upcoming 90th Annual General Meeting. The communication highlights that the final dividend, if declared, will be ₹13 per equity share. Members are informed that the last date to submit requisite documents for claiming nil or lower TDS is June 15, 2026. The company will use the PAN available in its records as of June 5, 2026, for TDS purposes. Members can find detailed information on the company's website and are advised to submit documents promptly to avoid higher TDS rates, with the possibility of claiming refunds later.

Cipla Ltd's Board of Directors approved the grant of stock options and employee stock appreciation rights (ESARs) under the Cipla Employee Stock Option Scheme 2013-A and the Cipla Employee Stock Appreciation Rights Scheme 2021. The board also approved the appointment of M/s Joshi Apte & Associates as Cost Auditors for FY 2026-27 and Mr. Sushrut Kulkarni as President & Global Chief – Integrated Product Development. The decisions were made at the board meeting held on May 13, 2026.

Cipla Ltd's Board of Directors, in its meeting held on May 13, 2026, approved the appointment of M/s Joshi Apte & Associates as Cost Auditors for the financial year 2026-27. The board also approved convening the 90th Annual General Meeting on June 25, 2026, and granted stock options and ESARs under the Cipla Employee Stock Option Scheme 2013-A and the Cipla Employee Stock Appreciation Rights Scheme 2021. Additionally, Mr. Sushrut Kulkarni was appointed as President & Global Chief – Integrated Product Development (IPD).

Cipla Ltd has announced the appointment of Mr. Sushrut Kulkarni as President & Global Chief – Integrated Product Development (IPD), member of Management Council and Senior Management Personnel (SMP) of the Company effective May 18, 2026. This decision was approved during the Board of Directors meeting held on May 13, 2026. The board also approved convening the 90th Annual General Meeting on June 25, 2026, granted stock options and ESARs, and appointed M/s Joshi Apte & Associates as Cost Auditors for FY 2026-27.

Cipla Ltd's board met on May 13, 2026, and approved convening the 90th Annual General Meeting on June 25, 2026. They approved grants of stock options and ESARs under the Cipla Employee Stock Option Scheme 2013-A and ESAR Scheme 2021. M/s Joshi Apte & Associates were appointed as Cost Auditors for FY 2026-27. Mr. Sushrut Kulkarni was appointed as President & Global Chief – Integrated Product Development (IPD), effective May 18, 2026.

Cipla Ltd announced its audited consolidated financial results for Q4 and FY 2025-26. FY26 revenue reached ₹28,163 Cr, the highest ever, with the One-India business surpassing ₹12,500 Cr. North America delivered $780 Mn in annual revenue, and Emerging Markets and Europe exceeded $400 Mn. Q4 revenue stood at ₹6,541 Cr with a PAT of ₹555 Cr. R&D investments were ₹509 Cr, representing 7.8% of sales for the quarter. The company holds a net cash position of ₹10,526 Cr.

Cipla Ltd's Board of Directors, in a meeting held on May 13, 2026, approved the audited financial results for the year ended March 31, 2026, and recommended a final dividend of ₹13 per equity share. The dividend, upon shareholder declaration, will be paid within 30 days from the AGM date. The record date for the dividend payment is set for June 5, 2026. For the quarter ended March 31, 2026, Cipla reported revenue from operations of ₹6,541.20 Cr and a net profit of ₹542.51 Cr.

Cipla Ltd's Board of Directors approved the audited financial results for the quarter and financial year ended March 31, 2026, and recommended a final dividend of ₹13 per equity share. The dividend, upon shareholder declaration, will be paid within 30 days from the Annual General Meeting. The record date for dividend payment is set for June 5, 2026. The company's revenue from operations for the year ended March 31, 2026, stood at ₹27,711.69 Cr.

Cipla Ltd's board approved audited financial results for the year ended March 31, 2026. The company reported revenue from operations of ₹27,711.69 Cr and a net profit of ₹542.51 Cr for the year ended March 31, 2026. The board also recommended a final dividend of ₹13 per equity share. The record date for the dividend is set as June 5, 2026, pending shareholder approval.

Cipla Ltd's wholly-owned subsidiary, Cipla USA Inc., has received final approval from the USFDA for its ANDA for Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation. This is the first AB-rated generic therapeutic equivalent of Ventolin® HFA, marketed by GlaxoSmithKline. The product, indicated for bronchospasm treatment and prevention, is expected to launch in the first half of FY 2026-27 in the USA. The total U.S. albuterol market is valued at approximately $1.5 billion.